In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Kyntra Bio, with a price target of $43.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matthew Keller has given his Buy rating due to a combination of factors, including advancing clinical milestones and solid financial positioning. He highlights that the Phase 2 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer is underway with an interim analysis targeted for 4Q26, and that prior investigator-sponsored combination data in this setting help support confidence ahead of this readout.
He also points to the inclusion of the FG-3180 PET imaging agent and thoughtful patient selection as design features that may enhance differentiation and reduce development risk. In parallel, submission of a Phase 3 protocol for roxadustat in LR-MDS, together with a cash balance of about $100 million expected to fund operations into 2028, underpins his view that Kyntra is well-capitalized to reach multiple value-creating catalysts, supporting his unchanged $43 price target and Buy rating.